citadel securities

Citadel Securities has upgraded SBA Communications (NASDAQL SBAC) from Reduce to Neutral and has lowered the price target from $34 to $32.

Citadel Securities has published a report on Questcor (NASDAQ: QCOR) raising the price target significantly and upgrading the company's stock from Neutral to Edge Positive. In the report, Citadel Securities wrote, "We anticipate a robust ramp in Acthar revenues from Nephrotic Syndrome based on a...

Citadel Securities has upgraded Questcor Pharmaceuticals (NASDAQ: QCOR) from Neutral to Edge Positive and has raised the price target from $23 to $44.

Citadel Securities has published a report on Forest Laboratories (NYSE: FRX) initiating coverage on the medicine developer. In the report, Citadel wrote, "We believe Forest revenue growth from fiscal 2013 to fiscal 2016 will be dependent on successful launches of recently approved drugs Teflaro,...

Citadel Securities has published a report on Biogen Idec Inc (NASDAQ: BIIB) intiating coverage on the biotech company. In the report, Citadel Securities wrote, "Biogen's hemophilia pipeline may provide an additional high-margin growth driver, in our view, although we await final data expected in...

Citadel Securities has published a report on Human Genome Sciences (NASDAQ: HGSI) initiating coverage on the biotech company. In the report, Citadel wrote, "We believe investors and the Street are singularly focused on Benlysta, resulting in the opportunity for potential upside on the “hidden...

Citadel Securities has published a report on Optimer Pharmaceuticals initiating coverage on the biopharm company. In the report, Citadel Securities wrote, "Although we view Dificid as a best-in-class treatment for Clostridium difficile (C. diff) associated infection, we believe competition from...

Citadel Securities has published a report on Dendreon (NASDAQ: DNDN) initiating coverage of the biotech company. In the report, Citadel Securities wrote, "We expect competitor data from Johnson & Johnson's oral prostate cancer drug ZYTIGA to be available during 2012, with an interim look...

Citadel Securities has published a report on Vertex (NASDAQ: VRTX) initiating coverage on the medicine developer. In the report, Citadel Securities wrote, "We are initiating coverage of Vertex Pharmaceuticals (VRTX) with a Neutral rating and $46 price target. While the launch of Incivek for HCV is...

Citadel has published a report on Seattle Genetics (NASDAQ: SGEN) initiating coverage on the biotech company. In the report, Citadel wrote, "Despite our bearish view on the Adcetris market opportunity, we believe the product is approvable based on Phase II data. While we believe approval could be...

Citadel Securities has initiated coverage on Seattle Genetics (NASDAQ: SGEN) with a Reduce rating and $10 PT.

Citadel Securities has initiated coverage on Vertex Pharmaceuticals (NASDAQ: VRTX) with a Neutral rating and $46 price target.

Citadel Securities has initiated coverage on Dendreon (NASDAQ: DNDN) with a Neutral rating and $10 price target.

Citadel Securities has initiated coverage on Optimer Pharmaceuticals (NASDAQ: OPTR) with a Neutral rating and $10 price target.

Citadel Securities has initiated coverage on Human Genome Sciences (NASDAQ: HGSI) with an Add rating and $25 price target.